60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q2 2025 financial results, highlighting a 19% year-over-year decline in net product revenues to $101,000 due to a temporary supply chain disruption. Despite lower revenues, the company achieved increased profitability with a gross profit of $51,000, up from $35,000 in Q2 2024.
Operating expenses decreased significantly to $1.86 million from $4.22 million in Q2 2024. The net loss improved to $1.84 million ($1.25 per share) compared to $4.29 million ($21.12 per share) in Q2 2024. With $1.97 million cash on hand and recent public offering proceeds of $4.46 million, the company projects runway through March 31, 2026.
Research studies indicate the total addressable U.S. market for ARAKODA for human babesiosis could reach $1.1 billion over the remaining 10-year patent life, with annual babesiosis incidence estimated between 25,000-380,000 cases.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) ha comunicato i risultati del secondo trimestre 2025, registrando un calo del 19% su base annua dei ricavi netti da prodotti a $101.000 a causa di un'interruzione temporanea della catena di approvvigionamento. Nonostante il minor fatturato, la società ha migliorato la redditività con un utile lordo di $51.000 (rispetto a $35.000 nel Q2 2024).
Le spese operative sono scese in modo significativo a $1.86 million da $4.22 million nel Q2 2024. La perdita netta si è ridotta a $1.84 million ($1.25 per azione) rispetto a $4.29 million ($21.12 per azione) nel Q2 2024. Con $1.97 million di cassa disponibile e proventi recenti da offerta pubblica pari a $4.46 million, la società stima liquidità sufficiente fino al 31 marzo 2026.
Studi di ricerca indicano che il mercato indirizzabile statunitense per ARAKODA nel trattamento della babesiosi umana potrebbe raggiungere un $1.1 billion nei restanti 10 anni di vita del brevetto, con un'incidenza annua stimata tra 25.000 e 380.000 casi.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) presentó los resultados del segundo trimestre de 2025, mostrando una reducción interanual del 19% en los ingresos netos por productos hasta $101,000 debido a una interrupción temporal en la cadena de suministro. A pesar de los menores ingresos, la compañía aumentó su rentabilidad con un beneficio bruto de $51,000, frente a $35,000 en el Q2 de 2024.
Los gastos operativos disminuyeron significativamente hasta $1.86 million desde $4.22 million en el Q2 de 2024. La pérdida neta mejoró hasta $1.84 million ($1.25 por acción) frente a $4.29 million ($21.12 por acción) en el Q2 de 2024. Con $1.97 million en efectivo y los ingresos recientes de una oferta pública por $4.46 million, la empresa proyecta tener fondos hasta el 31 de marzo de 2026.
Los estudios de investigación indican que el mercado direccionable total en EE. UU. para ARAKODA en la babesiosis humana podría alcanzar un $1.1 billion durante los 10 años restantes de la patente, con una incidencia anual estimada entre 25.000 y 380.000 casos.
60 Degrees Pharmaceuticals (NASDAQ: SXTP)는 2025년 2분기 실적을 발표하며, 공급망의 일시적 차질로 연간 기준 19% 감소한 제품 순매출이 $101,000를 기록했다고 밝혔습니다. 매출 감소에도 불구하고 회사는 $51,000의 총이익을 기록하며(2024년 2분기 $35,000) 수익성이 개선되었습니다.
영업비용은 2024년 2분기의 $4.22 million에서 크게 줄어 $1.86 million이 되었습니다. 당기순손실은 2024년 2분기의 $4.29 million ($21.12 주당)에서 개선되어 $1.84 million ($1.25 주당)을 기록했습니다. 현금 및 현금성자산은 $1.97 million이고 최근 공모로 $4.46 million을 조달해, 회사는 2026년 3월 31일까지 운영자금이 확보될 것으로 전망합니다.
연구에 따르면 인간 바베시아증 치료용 ARAKODA의 미국 내 총 주소가능 시장은 남은 특허 기간 10년 동안 $1.1 billion에 달할 수 있으며, 연간 발생 추정치는 25,000~380,000건 사이로 보고됩니다.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) a publié ses résultats du deuxième trimestre 2025, signalant une baisse de 19% en glissement annuel des revenus nets produits à 101 000 $ en raison d'une perturbation temporaire de la chaîne d'approvisionnement. Malgré la baisse des revenus, la société a amélioré sa rentabilité avec un profit brut de 51 000 $, contre 35 000 $ au T2 2024.
Les charges d'exploitation ont diminué de manière significative à $1.86 million contre $4.22 million au T2 2024. La perte nette s'est améliorée à $1.84 million (1,25 $ par action) contre $4.29 million (21,12 $ par action) au T2 2024. Avec 1,97 million $ de trésorerie et des produits récents d'une offre publique de 4,46 million $, la société prévoit une trésorerie suffisante jusqu'au 31 mars 2026.
Des études indiquent que le marché adressable total aux États-Unis pour ARAKODA dans la babesiose humaine pourrait atteindre $1.1 billion sur la durée de brevet restante de 10 ans, avec une incidence annuelle estimée entre 25 000 et 380 000 cas.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) veröffentlichte die Finanzergebnisse für das zweite Quartal 2025 und meldete einen jahresübergreifenden Rückgang der Nettoprodukterlöse um 19% auf $101.000, bedingt durch eine vorübergehende Störung der Lieferkette. Trotz geringerer Umsätze erzielte das Unternehmen eine höhere Profitabilität mit einem Bruttogewinn von $51.000 (gegenüber $35.000 im Q2 2024).
Die Betriebsausgaben sanken deutlich auf $1.86 million von $4.22 million im Q2 2024. Der Nettoverlust verbesserte sich auf $1.84 million ($1.25 pro Aktie) gegenüber $4.29 million ($21.12 pro Aktie) im Q2 2024. Mit liquiden Mitteln in Höhe von $1.97 million und Erlösen aus einer jüngsten Kapitalerhöhung in Höhe von $4.46 million rechnet das Unternehmen mit Mittelzufluss bis zum 31. März 2026.
Studien schätzen, dass der adressierbare US-Markt für ARAKODA bei der humanen Babesiose in den verbleibenden 10 Jahren des Patents $1.1 billion erreichen könnte, wobei die jährliche Inzidenz auf 25.000–380.000 Fälle geschätzt wird.
- None.
- Net product revenues declined 19% year-over-year to $101,000
- 17% decrease in ARAKODA pharmacy deliveries due to supply chain disruption
- Limited cash runway through March 31, 2026 without additional capital
- Babesiosis trial interim analysis dependent on minimum enrollment by October 2025
Insights
60 Degrees Pharmaceuticals reported lower Q2 revenue but improved profitability amid supply disruption; runway extended to March 2026 following recent capital raise.
60 Degrees Pharmaceuticals' Q2 2025 results reveal a company navigating supply challenges while improving its financial fundamentals. Net product revenue declined
Despite the revenue decline, gross profit increased to
The company's cash position stands at
Most intriguing is the market research suggesting the addressable U.S. market for ARAKODA in human babesiosis could approach
- A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model
$1.97 million cash on hand, runway through March 31, 2026
WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025.
While net product revenues declined compared to Q2 2024 due to a now resolved supply chain disruption, the Company reported an increase in profitability, largely attributed to cash-pay patients using KODATEF® (tafenoquine) 16-count boxes which were imported with U.S. Food and Drug Administration (FDA) consent to help mitigate a temporary disruption of supply of ARAKODA® 16-count boxes.
Provided the Company reaches minimum enrollment in its hospitalized babesiosis study prior to the end of the 2025 tick season in early October, the Company’s current cash position is expected to allow the trial’s interim analysis to be conducted prior to the need for additional capital.
Financial Highlights:
- Q2 2025 net product revenues decreased
19% year-over-year from$125 thousand to$101 thousand . This was associated with a decrease of17% in ARAKODA pharmacy deliveries, from 1,301 boxes (Q2 2024) to 1,082 16-count box equivalents (Q2 2025). This occurred due to a temporary disruption of supply of ARAKODA 16-count boxes which was incompletely mitigated by the introduction of the new 8-count ARAKODA bottle, and importation, with FDA consent, of KODATEF (tafenoquine 16-count boxes). New commercial lots of ARAKODA 16-count boxes are anticipated to enter the supply chain in September, 2025. - The Company achieved a gross profit of approximately
$51 thousand in the second quarter of 2025, compared to an approximate gross profit of$35 thousand in the second quarter of 2024. This was primarily due to lower overall cost of sales and via the sale of KODATEF 16-count boxes (which had fewer discounts/rebates). - Operating expenses were approximately
$1.86 million in the second quarter of 2025, compared to approximately$4.22 million in the second quarter of 2024. This was primarily due to the absence of one-off, non-cash, research and development costs that occurred during the same period in 2024. - Net loss attributable to common shareholders in the second quarter of 2025 was approximately
$1.84 million , or ($1.25) per share, compared to a net loss of approximately$4.29 million , or ($21.12) per share in the second quarter of 2024, representing a$2.45 million decrease in loss. - Based on current internal sales projections and considering the
$1.97 million in cash/cash equivalents on hand at June 30, 2025, and the net proceeds of approximately$4.46 million received from our recent July 15 public offering, we expect to remain financially viable through March 31, 2026, assuming no additional capital is raised. If we are successful in enrolling a total of at least 24 patients in our hospitalized babesiosis patient study before the end of the tick season in early October 2025, we expect the trial’s interim data analysis to be conducted prior to March 31, 2026.
Business Highlights for the Quarter Ended June 30, 2025
- The Company concluded several commercial research studies that collectively suggest that annual incidence of babesiosis is between 25,000 and 380,000 cases and that the total addressable U.S. market for ARAKODA for human babesiosis may approach
$1.1 billion over the remaining 10-year patent life. - A new 8-count bottle format of ARAKODA was introduced into the U.S. supply chain. This option will reduce the cost of ARAKODA for short-term travelers to malaria-endemic regions of the world.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
(310) 989-5666
FAQ
What were SXTP's Q2 2025 financial results?
How much cash does 60 Degrees Pharmaceuticals have and what is their runway?
What caused SXTP's revenue decline in Q2 2025?
What is the market potential for SXTP's ARAKODA in babesiosis treatment?
When will SXTP's ARAKODA supply chain issues be resolved?
